Capstone Investment Advisors
TARS icon

Capstone Investment Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Capstone Investment Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Buy
7,429
+3,630
+96% +$232K ﹤0.01% 1270
2026
Q1 		$267K Buy
+3,799
New +$265K ﹤0.01% 1410
2025
Q4 		– Sell
-11,501
Closed -$684K – 2036
2025
Q3 		$684K Buy
+11,501
New +$566K ﹤0.01% 1190

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capstone Investment Advisors's TARS Position: Q2 2026 in Review

Capstone Investment Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 96% in Q2 2026, buying an estimated $232K and bringing the position to 7,429 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Capstone Investment Advisors first reported a position in TARS in Q3 2025 and has held it in 3 quarters since. The position peaked at $684K in Q3 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Capstone Investment Advisors held 7,429 shares of Tarsus Pharmaceuticals worth $468K as of Q2 2026.
  • Capstone Investment Advisors bought 3,630 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $232K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1270 holding.
  • Capstone Investment Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Tarsus Pharmaceuticals position peaked at $684K in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.